Amanda Gordon
Family Medicine · San Antonio, TXNPI 1649749466
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 431 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Amgen at 26.4% of the total. 2025 is the largest year on record at $2,627, more than ten times the $13 reported in 2020. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 431 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novartis$1K
- UCB, Inc.$859
- Johnson & Johnson$767
- Lilly USA, LLC$616
- Mallinckrodt Hospital Products Inc.$578
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,89198%
- Education$1682%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 134 | $2,396 |
| Novartis | 56 | $1,242 |
| UCB, Inc. | 35 | $859 |
| Johnson & Johnson(3 entities) | 34 | $767 |
| Lilly USA, LLC | 23 | $616 |
| Mallinckrodt Hospital Products Inc. | 26 | $578 |
| Aurinia Pharma U.S., Inc. | 14 | $309 |
| GSK | 12 | $252 |
| E.r. Squibb & Sons, L.L.C. | 5 | $249 |
| Pfizer | 16 | $247 |
| Radius Health, Inc. | 13 | $244 |
| AstraZeneca(2 entities) | 14 | $222 |
| Boehringer Ingelheim | 5 | $194 |
| ANI Pharmaceuticals, Inc. | 10 | $192 |
| Fresenius Kabi USA, LLC | 5 | $105 |
| Ferring Pharmaceuticals Inc. | 7 | $105 |
| Actelion Pharmaceuticals US, Inc. | 4 | $104 |
| Genentech USA, Inc. | 4 | $67 |
| Invivyd Inc | 2 | $46 |
| AbbVie | 1 | $43 |
| Sandoz | 2 | $36 |
| Almatica Pharma LLC | 1 | $28 |
| Sobi, Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Octapharma USA, Inc. | 1 | $20 |
| Celltrion USA Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $14 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,059 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 126 | $6,810 |
| Cevimeline Hcl | 12 | $2,295 |
| MethotrexateMethotrexate Sodium | 81 | $2,195 |
| Allopurinol | 20 | $399 |
| Prednisone | 43 | $272 |
| Gabapentin | 28 | $269 |
| Meloxicam | 12 | $170 |
| Tramadol Hcl | 22 | $86 |
| Alendronate Sodium | 14 | $17 |
Paid to pharmacies, not to this prescriber.
Other family medicine in San Antonio
- Aaron KingSan Antonio$1.1M
- Solomon PaleySan Antonio$136K
- Sarah SamreenSan Antonio$133K
- Melissa WalkerSan Antonio$53K
- Paul SaenzSan Antonio$50K
- Carlos CamposNew Braunfels$1.5M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.